Previous 10 | Next 10 |
2024-03-05 09:30:00 ET It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting time, and there's reason to believe that the popular players of today wil...
2024-03-02 09:30:00 ET You can find growth stocks in every sector. With healthcare making up nearly one-fifth of the U.S. economy, it's a great place to look. Three Motley Fool contributors have identified what they think are magnificent growth stocks to buy in March -- and all of them ...
2024-02-29 09:00:00 ET The "Magnificent Seven," a group of market-leading tech companies, is so named for several reasons. Here are three: First, they've all delivered outsized returns over the past decade or so. Second, all seven are leaders in their respective niches of the tech sector. T...
2024-02-26 05:52:00 ET My first response when thinking about the ultimate growth stock to buy with $1,000 right now was to go with a high-flying AI stock. But the more I deliberated, the less comfortable I was choosing one of those stocks. Don't get me wrong. I like (and own) several gr...
2024-02-25 10:00:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For the fourth quarter of 2023, Aristo...
2024-02-24 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-23 08:10:18 ET Read the full article on Seeking Alpha For further details see: Vertex gets EU backing for label expansion of Kalydeco in cystic fibrosis
- If approved, KALYDECO ® will be the first and only medicine approved in Europe to treat the underlying cause of cystic fibrosis in babies as young as 1 month with specific mutations in the CFTR gene - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European...
2024-02-21 08:48:22 ET More on CRISPR Therapeutics Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range Is Cri...
2024-02-21 07:13:01 ET Regeneron ( NASDAQ: REGN ) and Vertex Pharmaceuticals ( NASDAQ: VRTX ) have crossed $100B in market capitalization for the first time, joining two other giants in the biotech industry, Amgen ( AMGN ) and AbbVie ( ABBV ).... Read the full ...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...